The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan
Pompe disease Newborn screening (NBS) aims at diagnosing patients with infantile-onset Pompe disease (IOPD) early enough so a timely treatment can be instituted. Since 2015, the National Taiwan University NBS Center has changed the method for Pompe disease NBS from fluorometric assay to tandem mass...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | International Journal of Neonatal Screening |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2409-515X/6/2/30 |
| _version_ | 1797571831350165504 |
|---|---|
| author | Shu-Chuan Chiang Yin-Hsiu Chien Kai-Ling Chang Ni-Chung Lee Wuh-Liang Hwu |
| author_facet | Shu-Chuan Chiang Yin-Hsiu Chien Kai-Ling Chang Ni-Chung Lee Wuh-Liang Hwu |
| author_sort | Shu-Chuan Chiang |
| collection | DOAJ |
| description | Pompe disease Newborn screening (NBS) aims at diagnosing patients with infantile-onset Pompe disease (IOPD) early enough so a timely treatment can be instituted. Since 2015, the National Taiwan University NBS Center has changed the method for Pompe disease NBS from fluorometric assay to tandem mass assay. From 2016 to 2019, 14 newborns were reported as high-risk for Pompe disease at a median age of 9 days (range 6–13), and 18 were with a borderline risk at a median age of 13 days (9–28). None of the borderline risks were IOPD patients. Among the 14 at a high-risk of Pompe disease, four were found to have cardiomyopathy, and six were classified as potential late-onset Pompe disease. The four classic IOPD newborns, three of the four having at least one allele of the cross-reactive immunologic material (CRIM)-positive variant, started enzyme replacement therapy (ERT) at a median age of 9 days (8–14). Western Blot analysis and whole gene sequencing confirmed the CRIM-positive status in all cases. Here, we focus on the patient without the known CRIM-positive variant. Doing ERT before knowing the CRIM status created a dilemma in the decision and was discussed in detail. Our Pompe disease screening and diagnostic program successfully detected and treated patients with IOPD in time. However, the timely exclusion of a CRIM-negative status, which is rare in the Chinese population, is still a challenging task. |
| first_indexed | 2024-03-10T20:46:14Z |
| format | Article |
| id | doaj.art-b5b1177bb538425195dfe33bd2638289 |
| institution | Directory Open Access Journal |
| issn | 2409-515X |
| language | English |
| last_indexed | 2024-03-10T20:46:14Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Neonatal Screening |
| spelling | doaj.art-b5b1177bb538425195dfe33bd26382892023-11-19T20:19:56ZengMDPI AGInternational Journal of Neonatal Screening2409-515X2020-04-01623010.3390/ijns6020030The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in TaiwanShu-Chuan Chiang0Yin-Hsiu Chien1Kai-Ling Chang2Ni-Chung Lee3Wuh-Liang Hwu4Department of Medical Genetics, National Taiwan University Hospital, Taipei 100, TaiwanDepartment of Medical Genetics, National Taiwan University Hospital, Taipei 100, TaiwanDepartment of Medical Genetics, National Taiwan University Hospital, Taipei 100, TaiwanDepartment of Medical Genetics, National Taiwan University Hospital, Taipei 100, TaiwanDepartment of Medical Genetics, National Taiwan University Hospital, Taipei 100, TaiwanPompe disease Newborn screening (NBS) aims at diagnosing patients with infantile-onset Pompe disease (IOPD) early enough so a timely treatment can be instituted. Since 2015, the National Taiwan University NBS Center has changed the method for Pompe disease NBS from fluorometric assay to tandem mass assay. From 2016 to 2019, 14 newborns were reported as high-risk for Pompe disease at a median age of 9 days (range 6–13), and 18 were with a borderline risk at a median age of 13 days (9–28). None of the borderline risks were IOPD patients. Among the 14 at a high-risk of Pompe disease, four were found to have cardiomyopathy, and six were classified as potential late-onset Pompe disease. The four classic IOPD newborns, three of the four having at least one allele of the cross-reactive immunologic material (CRIM)-positive variant, started enzyme replacement therapy (ERT) at a median age of 9 days (8–14). Western Blot analysis and whole gene sequencing confirmed the CRIM-positive status in all cases. Here, we focus on the patient without the known CRIM-positive variant. Doing ERT before knowing the CRIM status created a dilemma in the decision and was discussed in detail. Our Pompe disease screening and diagnostic program successfully detected and treated patients with IOPD in time. However, the timely exclusion of a CRIM-negative status, which is rare in the Chinese population, is still a challenging task.https://www.mdpi.com/2409-515X/6/2/30infantile-onset Pompe diseaseGAA sequencingimmune modulation therapyenzyme replacement therapycross-reactive immunologic material |
| spellingShingle | Shu-Chuan Chiang Yin-Hsiu Chien Kai-Ling Chang Ni-Chung Lee Wuh-Liang Hwu The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan International Journal of Neonatal Screening infantile-onset Pompe disease GAA sequencing immune modulation therapy enzyme replacement therapy cross-reactive immunologic material |
| title | The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan |
| title_full | The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan |
| title_fullStr | The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan |
| title_full_unstemmed | The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan |
| title_short | The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan |
| title_sort | timely needs for infantile onset pompe disease newborn screening practice in taiwan |
| topic | infantile-onset Pompe disease GAA sequencing immune modulation therapy enzyme replacement therapy cross-reactive immunologic material |
| url | https://www.mdpi.com/2409-515X/6/2/30 |
| work_keys_str_mv | AT shuchuanchiang thetimelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT yinhsiuchien thetimelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT kailingchang thetimelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT nichunglee thetimelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT wuhlianghwu thetimelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT shuchuanchiang timelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT yinhsiuchien timelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT kailingchang timelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT nichunglee timelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan AT wuhlianghwu timelyneedsforinfantileonsetpompediseasenewbornscreeningpracticeintaiwan |